Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611775 | 0.79 | PTPN1 (0.51) | PTPN1ABCB1NOX1ADORA3ADORA2B | |
| SCHEMBL13679695 | 0.79 | NOX1 (0.45) | PTPN1NOX1ADORA3ADORA2BALOX5 | |
| SCHEMBL13679702 | 0.77 | PTPN1 (0.72) | PTPN1NOX1ADORA3ADORA2BALOX5 | |
| SCHEMBL13679659 | 0.77 | NOX1 (0.61) | PTPN1ABCB1NOX1ALOX5KDM4E | |
| SCHEMBL8797319 | 0.77 | PTPN1 (0.72) | PTPN1NOX1ADORA3ADORA2BALOX5 | |
| SCHEMBL13679673 | 0.77 | PTPN1 (0.43) | PTPN1ABCB1NOX1ADORA3ADORA2B | |
| SCHEMBL13679657 | 0.76 | NOX1 (0.60) | PTPN1ABCB1NOX1ALOX5KDM4E | |
| SCHEMBL13679693 | 0.76 | PTPN1 (0.50) | PTPN1ABCB1ADORA3ADORA2BRAF1 | |
| SCHEMBL3831111 | 0.76 | PTPN1 (0.48) | PTPN1ABCB1ADORA3ADORA2BRAF1 | |
| SCHEMBL13679716 | 0.76 | ABCB1 (0.84) | PTPN1ABCB1NOX1ALOX5MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041647-A1 | PRECLINICAL DEVELOPMENT OF A ROMIDEPSIN NANOPARTICLE DEMONSTRATES SUPERIOR TOLERABILITY AND EFFICACY IN MODELS OF HUMAN T-CELL LYMPHOMA AND LARGE GRANULAR LYMPHOCYTE LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041647-A1 | PRECLINICAL DEVELOPMENT OF A ROMIDEPSIN NANOPARTICLE DEMONSTRATES SUPERIOR TOLERABILITY AND EFFICACY IN MODELS OF HUMAN T-CELL LYMPHOMA AND LARGE GRANULAR LYMPHOCYTE LEUKEMIA | MALT1, HDAC1, HDAC3 | PTPN1 937/4885ABCB1 200/4885NOX1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.